Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1381-1384

  Saldanha, Gerald ^a   Potter, Linda ^a   Shendge, Priya ^a   Osborne, Joy ^b   Nicholson, Steve ^a   Yii, Ngiwieh ^b   Varma, Sanjay ^b   Aslam, Muhammad Imran ^b   Elshaw, Shona ^a   Papadogeorgakis, Eftychios ^a   Pringle, J Howard ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 21;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER TISSUE; CUTANEOUS MELANOMA; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPIDERMIS; GENE LOCUS; HISTOPATHOLOGY; HUMAN; LETTER; MEDICAL SOCIETY; MELANOCYTE; MELANOMA; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84876684076     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.477     Document Type: Letter

References (13)

1. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
2. Calin GA, Dumitru CD, Shimizu M et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-9
3. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
4. Friedman EB, Shang S, Vega-Saenz de Miera E et al. (2012) Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 10:155
5. Griffiths-Jones S, Saini HK, van Dongen S et al. (2008) miRBase: tools for microRNA geno-mics. Nucleic Acids Res 36:D154-8
6. Grignol V, Fairchild ET, Zimmerer JM et al. (2011) miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br J Cancer 105: 1023-9
7. Jiang L, Lv X, Li J et al. (2011) The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem 114:582-8
8. Krengel S, Hauschild A, Schafer T (2006) Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 155:1-8
9. Mitchell PS, Parkin RK, Kroh EM et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-8
10. Robert C, Thomas L, Bondarenko I et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-26
11. Satzger I, Mattern A, Kuettler U et al. (2012) MicroRNA-21 is upregulated in malignant melanoma and influences apoptosis of mela-nocytic cells. Exp Dermatol 21:509-14
12. Volinia S, Calin GA, Liu CG et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-61
13. Zhang L, Huang J, Yang N et al. (2006) MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103:9136-41